The Supplement Industry's Ongoing Identity Crisis
The dietary supplement industry occupies a peculiar regulatory space. In the United States, supplements are regulated as food, not drugs — meaning companies do not need to prove their products are effective or even safe before selling them. The FDA can only act after harm is demonstrated.
This framework, established by the 1994 Dietary Supplement Health and Education Act (DSHEA), has produced an industry worth over $60 billion annually in the US alone — and a quality landscape that ranges from rigorously validated products to adulterated garbage sold in identical packaging.
By 2026, several forces have started to change this picture. Some meaningfully.
Related: Want to put this into practice? Try our Supplement Stack Audit to get started, and check out Anti-Placebo: Proving It Doesn't Work Has Value for more context.
What Has Actually Changed Since 2020
Third-Party Testing Has Become Table Stakes
Five years ago, third-party certification (NSF, USP, Informed Sport) was a differentiator. Today, any serious supplement brand selling to informed consumers has at minimum a COA (certificate of analysis) available and many have formal third-party certification.
This does not mean all supplements are now verified — the mass market is still filled with uncertified products. But the consumer-facing supplement brands targeting health-conscious buyers have largely moved toward verification as a baseline.
GMP Compliance Is More Consistently Enforced
Good Manufacturing Practice (GMP) regulations for supplement manufacturers have been progressively enforced more strictly by the FDA. Warning letters and facility closures for GMP violations increased substantially between 2020 and 2025. This has raised the manufacturing floor — fewer blatant quality disasters — but it has not addressed the fundamental issue that potency and ingredient accuracy are not routinely verified.
GMP compliance ensures a supplement was made in a clean facility with documented processes. It does NOT guarantee the label is accurate. A manufacturer can follow GMP perfectly and still put 50% of the labeled dose in a capsule if the formulation itself is wrong. Third-party testing of finished products is the only assurance of label accuracy.
Novel Ingredient Categories Have Exploded
The decade between 2015 and 2025 saw several categories emerge from niche to mainstream: functional mushrooms, peptides, nootropics, longevity compounds, and GLP-1 adjacent supplements. Each new category has replicated the same quality distribution that older categories had — a few quality-focused brands surrounded by a much larger number of underdosed, mislabeled, or ineffective products.
Private Label Has Proliferated
The rise of contract manufacturing and Amazon-based private label brands has made it easier than ever to put a supplement on the market with minimal investment. Many private label products are identical formulations with different branding. Some are quality products; many are not. Brand name alone is no longer a useful quality signal.
The Current Regulatory Landscape
FDA NDI Notifications
New Dietary Ingredient (NDI) notifications are required for ingredients not marketed before 1994. Enforcement of NDI requirements has strengthened. Several novel ingredients popular in biohacking communities — including some peptides and specific nootropic compounds — have faced increased regulatory scrutiny.
FTC Advertising Enforcement
The Federal Trade Commission has increased enforcement against supplement companies making unsupported health claims. Settlements have involved companies claiming products "boost immunity," "reduce inflammation," or provide specific disease-related benefits without substantiation.
This is relevant to consumers because it means the most egregious claims have decreased — but subtler implied claims ("supports healthy immune function") remain common and are not meaningfully regulated.
The regulatory definition of a permissible supplement health claim is a "structure/function" claim: "Vitamin C supports immune function" is permitted. "Vitamin C prevents colds" is not. Practically speaking, the line between these two is blurry in marketing copy, and companies routinely push against it. Learn to read the implied claim, not just the literal one.
Emerging EU Regulation
The European Union has moved toward stricter novel food regulations that affect which supplements can legally be sold. Several compounds widely available in the US — including some mushroom extracts and specific amino acids — face restrictions or pending review in EU markets. This divergence creates a situation where consumers in different regions access different products.
What Quality Actually Looks Like in 2026
The Certification Hierarchy
Not all third-party certifications are equal:
| Certification | What It Verifies |
|---|---|
| NSF Certified for Sport | Label accuracy, banned substance testing, GMP |
| Informed Sport / Informed Choice | Banned substance testing, label verification |
| USP Verified | Label accuracy, purity, GMP |
| NSF Contents Claim Standard | Label accuracy (not sport-specific) |
| Independently tested (COA) | Potency at time of testing (no ongoing verification) |
For general supplement use, USP or NSF certification is the highest standard. For athletes subject to drug testing, Informed Sport or NSF Certified for Sport adds the banned substance screen.
Bioavailability: The Next Quality Frontier
The industry is increasingly competing on formulation quality — not just purity but bioavailability. Patented forms with clinical backing (KSM-66 ashwagandha, Magtein magnesium threonate, Longvida curcumin) command premiums for documented absorption advantages.
The generic vs. patented form debate is real and matters for certain ingredients more than others. Magnesium form differences are well-established. Curcumin bioavailability differences are dramatic (100x between standard and enhanced forms). Vitamin K2 form (MK-4 vs. MK-7) affects half-life significantly.
Pros
- +Third-party testing has become more available and more consumer-facing
- +GMP enforcement has raised the manufacturing floor
- +More quality supplement brands have emerged competing on transparency
- +Information about ingredient quality and bioavailability is more accessible
- +Patented ingredient forms with clinical validation are more widely available
Cons
- -Private label proliferation means brand name is still not a quality proxy
- -NDI enforcement has pushed some novel ingredients into gray markets
- -Novel ingredient categories (mushrooms, peptides) still have significant quality variation
- -Amazon marketplace remains difficult to police for quality
- -Third-party certification covers a minority of total supplements sold
How to Evaluate a Supplement in 2026
A practical checklist:
-
Is the active ingredient a researched form? KSM-66 or Sensoril ashwagandha, not generic root powder. Magtein or magnesium glycinate, not magnesium oxide.
-
Is the dose within the studied range? Look up the clinical trials for the ingredient and compare the dose to what was studied. Many supplements use "label doses" that are a fraction of studied amounts.
-
Does the brand have third-party certification or publicly available COAs? NSF, USP, Informed Sport, or batch-level COAs available on request are acceptable.
-
Can you identify who manufactures it? House brands manufactured in the same facility as dozens of private labels is a yellow flag.
-
What does their returns/customer service look like? This is a soft signal, but companies confident in their quality tend to have strong return policies.
Tracking Your Supplement Stack Quality
Be the first to try Prova
We're building an app to track whether supplement quality actually works. Join the waitlist.
Knowing whether a supplement is working requires knowing that what you're taking matches the label. This is why structured tracking and single-variable experiments matter — if you are running experiments on five untested supplements simultaneously, you cannot identify which one is responsible for any observed change.
The Bottom Line
The supplement industry in 2026 is better regulated and more transparent than it was a decade ago — but it is still far from a trustworthy market across the board. Third-party certification, researched ingredient forms, and clinical-range dosing remain the three filters that separate quality products from expensive inert capsules. The informed consumer still needs to do due diligence that should, in a better-regulated industry, be unnecessary.